Fair points...not that I agree with most of them, at least you put some thought into them. Rare on this board...
I'll retort in reverse if you don't mind.
Yes, you would entertain any offers, regardless of the landscape not being defined. Acquiring companies will look at KPTI much like a pre-commercial enterprise. If they saw value in the molecule someone would throw an offer together to take it off the board. RP does not make that call on any level ...the BOD and the institutional investor will have more to say about that than RP. If your scenarios in your first paragraph were likely, someone would gladly through $5B at KPTI t(which they would take in a heartbeat) to get that platform and future revenue stream. Could you be right? Perhaps, however very few if any are seeing it the way you are seeing. Doesn't mean you are wrong...just saying it highly unlikely.
Disagree that the investment banks and big phama's getting outsmarted by the small fledging biotech's. They are not merely buying revenue streams like in years past. They are more interested in buying platforms and technology of which the fruits of those deals may not be seen for over a decade. To call any deal a failure in the first 5 years shows you have little experience in M&A, which is ok. My guess is you are a commercial employee and not a finance person. You know a little about a little but not a lot about this. The big investment banks don't stay in business by getting routinely outsmarted.
I disagree with your sentiment on development in competitive markets KPTI will play in and what the revenue potential for those indications. Seli is not going to be the best or theonly therapy in any of those future indications. Commercial execution at KPTI has been underwhelming. High turnover, flat revenue and stagnation in share doesn't scream commercial success for future indications.
